Improved survival and treatment for chronic blood disorders
Tuesday, May 17, 2011 - 14:30
in Health & Medicine
New research shows that hydroxyurea, one type of cytotoxic treatment for chronic myeloproliferative blood disorders, does not increase the risk of developing acute leukemia, as had previously been suspected. Rather, it is the disease itself that mainly increases this risk. Another new study by the same group of researchers shows that mortality from chronic myeloid leukaemia has decreased sharply since the approval of the drug Imatinib as a standard treatment in 2001.
